Arrowhead Pharmaceuticals Reports Strong Q1 Profitability Driven by REDEMPLO Launch and Pipeline Progress

summarizeSummary

Arrowhead Pharmaceuticals reported a significant return to profitability in its fiscal first quarter, driven by the successful commercial launch of its first FDA-approved product, REDEMPLO®, and strong pipeline advancements.

check_boxKey Events · Earnings and Guidance · ARWR

• Strong Financial Performance

  The company reported a net income of $30.8 million ($0.22 diluted EPS) for the fiscal first quarter ended December 31, 2025, a significant improvement from a net loss of $173.1 million in the prior year. Revenue surged to $264.0 million from $2.5 million year-over-year.

• First Commercial Product Launch

  Arrowhead successfully launched REDEMPLO® (plozasiran) in the U.S. following its FDA approval on November 18, 2025, for familial chylomicronemia syndrome (FCS). Initial prescription and reimbursement trends are encouraging, with over 100 prescriptions received to date. REDEMPLO also received regulatory approvals in China and Canada.

• Promising Obesity Program Data

  Interim clinical data for RNAi-based obesity candidates ARO-INHBE and ARO-ALK7 showed significant weight loss and improved body composition. ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16, approximately a two-fold improvement over tirzepatide alone.

• Significant Partnership and Milestone Payments

  The company received a $200 million upfront payment from Novartis for a global licensing and collaboration agreement for ARO-SNCA, with potential for up to $2 billion in additional milestones. A $200 million milestone payment was also triggered from Sarepta Therapeutics for SRP-1003.

auto_awesomeAnalysis · ARWR · Life Sciences

This 8-K filing reports exceptionally strong fiscal first-quarter results, marking a significant turnaround to profitability for Arrowhead Pharmaceuticals. The company's transition to a commercial-stage entity with the successful launch of REDEMPLO® in the U.S., coupled with its approval in China and Canada, is a major milestone. The substantial increase in revenue and net income reflects the impact of recent strategic partnerships and product advancements. Furthermore, the promising interim clinical data from its obesity programs and the initiation of new clinical trials for ASCVD and tauopathies demonstrate robust pipeline progress. The successful closing of a $930 million capital raise, a $200 million milestone payment from Sarepta, and a $200 million upfront payment from Novartis significantly bolster the company's financial position, providing ample resources for future development and commercialization efforts. This comprehensive update signals strong operational execution and a positive trajectory for the company.